Ernest Ramsay Camp

Ernest Ramsay Camp, M.D., FACS

Professor and Chief, Division of Surgical Oncology

(832) 957-6500

Positions

Professor and Chief, Division of Surgical Oncology: ��Ƶ of Medicine

Olga Keith Wiess Chair of Surgery: ��Ƶ of Medicine

Chief, Oncology Service Line: Baylor St. Luke's Medical Center

Addresses

Dan L Duncan Comprehensive Cancer Center (Clinic): O’Quinn Medical Tower at McNair
1919 Old Spanish Trail
Houston, TX, 77054
United States
Phone: (832) 957-6500

Education

Fellowship at The University of Texas M.D. Anderson Cancer Center: Houston, United States; Surgical Oncology

Postdoctoral Training at The University of Texas M.D. Anderson Cancer Center: Houston, United States; T32 Research Fellowship

Residency at Shand’s Hospital, University of Florida: Gainesville

MS from Medical University of South Carolina: Charleston; Clinical Research

MD from Medical University of South Carolina: Charleston

BA from Davidson College: Davidson; Chemistry

Certifications

American Board of Surgery

Professional Interests

Surgical oncology
Pancreatic cancer
Pancreaticobiliary malignancies
Gastric cancer and other gastric malignancies
Sarcoma
Melanoma
Small bowel tumors
Neuroendocrine tumors
Gasrointestinal tumors
Minimally invasive surgery
HIPEC

Professional Statement

Dr. E. Ramsay Camp, M.D., FACS, is professor and chief of the Division of Surgical Oncology in the Michael E. DeBakey Department of Surgery at ��Ƶ of Medicine. He completed his undergraduate degree at Davidson College and his medical degree at the Medical University of South Carolina. He performed his general surgery training at the Shand's Hospital at the University of Florida and went on to complete a surgical oncology fellowship at the University of Texas M.D. Anderson Cancer Center in 2007. He joins the faculty of Baylor as the Chief of Surgical Oncology coming from the Medical Unversity of South Carolina where he has practiced for the last twelve years. Dr. Camp’s clinical practice and expertise has focused on treating patients with complex gastrointestinal tumors including pancreatic and gastric malignancies as well as sarcoma and melanoma.

Dr. Camp has an active externally funded research laboratory supported by a VA Merit Award with a focus on mechanisms of chemotherapy and radiation resistance in pancreatic and colorectal cancer. He is a fellow of the American College of Surgeons and a member of various oncology societies including the American Surgical Association, the Southern Surgical Association, Society of Surgical Oncology, American Society of Clinical Oncology, American Association of Cancer Research, National Surgical Adjuvant Breast and Bowel Project (NSABP), Southwest Oncology Group (SWOG), and the American College of Surgeons Oncology Group (ACOSOG).

Websites

Division of Surgical Oncology

Surgical Translational Oncology Laboratory

Videos

Selected Publications

Bowers JS, Bailey SR, Rubinstein MP, Paulos CM, and Camp ER. " Genomics meets immunity in pancreatic cancer: Current research and future directions for pancreatic adenocarcinoma immunotherapy. " Oncology Reviews. ;
Janakiraman H, Zhu Y, Becker SA, Wang C, Cross A, Curl E, Lewin D, Hoffman BJ, Warren GW, Hill EG, Timmers C, Findlay VJ, and Camp ER. " Modeling rectal cancer to advance neoadjuvant precision therapy. " International Journal of Cancer. ;
Riley JM, Cross AW, Paulos C, Rubinstein MP, Wrangle J, and Camp ER. " The clinical implications of immunogenomics in colorectal cancer: A path for precision medicine. " Cancer. ;
Zhu Y, Wang C, Becker SA, Hurst K, Nogueira LM, Findlay VJ and Camp ER. " miR-145 antagonizes SNAI1-mediated stemness and radiation resistance in colorectal cancer. " Molecular Therapeutics. ;
Esnaola NF, Meyer JE, Karachristos A, Maranki JL, Camp ER, Denlinger CS. " Evaluation and management of intrahepatic and extrahepatic cholangiocarcinoma. " Cancer. ;
Skodepole A, Engelhart K, Kutlu O, Lancaster WP, Abbott A and Camp ER. " High Mitotic Rate Predicts Sentinel Lymph Node Involvement in Thin Melanomas. " J Surg Res. ;
Camp ER, and Ellis LM. " CCR 20th Anniversary Commentary: RAS as a Biomarker for EGFR--Targeted Therapy for Colorectal Cancer-From Concept to Practice. " Clinical Cancer Research. ;
Findlay VJ, Wang C, Quirk D, Hurst K, Vaena S, Watson DK, and Camp ER. " SNAI2 modulates colorectal cancer 5-fluorouracil sensitivity through miR145 repression. " Molecular Cancer Therapeutics. ;
Esnaola NF, Chaudhary UB, O'Brien P, Garrett-Mayer E, Camp ER, Thomas M, Cole DJ, Montero AJ, Hoffman B, Romagnuolo J, and Marshall DT. " Phase II Trial of Induction Gemcitabine, Oxaliplatin, and Cetuximab followed by Selective Capecitabine-Based Chemoradiation in Patients with Nonmetastatic, Locally Advanced Pancreatic Cancer. " Int J Radiat Oncol Biol Phys. ;
Findlay VJ, Wang C, Watson DK, and Camp ER. " Epithelial -to-mesenchymal transition and the cancer stem cell phenotype: insights from cancer biology with therapeutic implications for colorectal cancer. " Cancer Gene Therapy. ;

to edit your profile

������Ƶ